Measure the Serum Level of Homocysteine in Acne Patients Before and After Oral Isotretinoin.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-15

Study Completion Date

2021-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Serum homocysteine level in Acne patients before and after oral Isotretinoin and Correlation between serum level of homocysteine in acne patients before and after Oral isotretinoin treatment

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Homocysteine in Acute Coronary Syndrome

NCT05125419

Acute Coronary Syndrome

COMPLETED

Homocysteine and Coronary Artery Disease

NCT06675890

Coronary Arterial Disease (CAD)

COMPLETED

Biotin Status in Pregnancy

NCT00894920

Biotin Deficiency

COMPLETED NA

Effects of Homocysteine in Myocardial Infarction Patients in a Tertiary Care Hospital of Pakistan

NCT05011032

Homocystine; Metabolic Disorder

WITHDRAWN NA

Homocystinuria: Treatment With N-Acetylcysteine

NCT00483314

Homocystinuria

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Acne vulgaris is a common chronic inflammatory disease of the skin. It is found in about 80% of young adults and adolescents. It is a disease that affects the pilosebaceous units of the skin and may result in inflammatory or non-inflammatory lesions,Oral isotretinoin (13-cis-retinoic acid) is the only drug that counteracts all the pathogenetic mechanisms that contribute to the development of acne The standard dose of isotretinoin is 0.5 to 1 mg/kg per day for 4 months to a cumulative dose of 120-140 mg/kg is effective in the management of acne vulgaris The scope of our study is to detect serum homocysteine level in acne patient befor and after oral isotrtinoin treatment

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

group of patients and group of control

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patient group

Patients were treated with Isotretinoin in a dose (from 20 to 40) for 3 months and serum homocysteine were assessed before and after treatment

Group Type ACTIVE_COMPARATOR

Isotretinoin

Intervention Type DRUG

Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration

Control group

Assessment of serum YKL40 in healthy individuals

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isotretinoin

Isotretinoin is a vitamin-A derivative for treatment of moderate to severe acne used in a dose from 20-40 mg for 3 months duration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of both sexes with acne vulgaris

Exclusion Criteria

* Patients with history of malignancies.
* Patients with renal and hepatic dysfunction.
* Cardiac patient.
* Pregnant, lactating and female welling to have pregnancy in the period of study.
* Patient with absorption disorder.
* Patient with history of favism.
* Patient has already been treated with isotretinoin.

Minimum Eligible Age

15 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No